Alpha Tau Medical Statistics
Total Valuation
DRTS has a market cap or net worth of $628.39 million. The enterprise value is $568.99 million.
Important Dates
The next estimated earnings date is Monday, May 18, 2026, after market close.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DRTS has 88.01 million shares outstanding. The number of shares has increased by 15.24% in one year.
| Current Share Class | 88.01M |
| Shares Outstanding | 88.01M |
| Shares Change (YoY) | +15.24% |
| Shares Change (QoQ) | +1.06% |
| Owned by Insiders (%) | 16.25% |
| Owned by Institutions (%) | 2.91% |
| Float | 45.32M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 651.92 |
| PB Ratio | 8.15 |
| P/TBV Ratio | 8.15 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.45, with a Debt / Equity ratio of 0.18.
| Current Ratio | 7.45 |
| Quick Ratio | 6.99 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -121.87 |
Financial Efficiency
Return on equity (ROE) is -61.00% and return on invested capital (ROIC) is -31.84%.
| Return on Equity (ROE) | -61.00% |
| Return on Assets (ROA) | -27.55% |
| Return on Invested Capital (ROIC) | -31.84% |
| Return on Capital Employed (ROCE) | -44.45% |
| Weighted Average Cost of Capital (WACC) | 9.83% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$352,289 |
| Employee Count | 121 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, DRTS has paid $121,000 in taxes.
| Income Tax | 121,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +183.33% in the last 52 weeks. The beta is 1.05, so DRTS's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +183.33% |
| 50-Day Moving Average | 7.21 |
| 200-Day Moving Average | 4.84 |
| Relative Strength Index (RSI) | 51.93 |
| Average Volume (20 Days) | 212,002 |
Short Selling Information
The latest short interest is 573,837, so 0.65% of the outstanding shares have been sold short.
| Short Interest | 573,837 |
| Short Previous Month | 594,941 |
| Short % of Shares Out | 0.65% |
| Short % of Float | 1.27% |
| Short Ratio (days to cover) | 1.90 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -42.29M |
| Pretax Income | -42.51M |
| Net Income | -42.63M |
| EBITDA | -41.06M |
| EBIT | -42.29M |
| Earnings Per Share (EPS) | -$0.53 |
Full Income StatementBalance Sheet
The company has $73.13 million in cash and $13.73 million in debt, with a net cash position of $59.40 million or $0.67 per share.
| Cash & Cash Equivalents | 73.13M |
| Total Debt | 13.73M |
| Net Cash | 59.40M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 77.10M |
| Book Value Per Share | 0.88 |
| Working Capital | 67.79M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$26.68 million and capital expenditures -$6.08 million, giving a free cash flow of -$32.76 million.
| Operating Cash Flow | -26.68M |
| Capital Expenditures | -6.08M |
| Depreciation & Amortization | 1.23M |
| Net Borrowing | n/a |
| Free Cash Flow | -32.76M |
| FCF Per Share | -$0.37 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
DRTS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.24% |
| Shareholder Yield | -15.24% |
| Earnings Yield | -6.78% |
| FCF Yield | -5.21% |
Analyst Forecast
The average price target for DRTS is $8.67, which is 21.43% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.67 |
| Price Target Difference | 21.43% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
